PMID- 27479640
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20170522
IS  - 1527-1315 (Electronic)
IS  - 0033-8419 (Linking)
VI  - 282
IP  - 1
DP  - 2017 Jan
TI  - Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous 
      Ovarian Cancer: A Single-Institution Experience with 244 Patients.
PG  - 160-170
LID - 10.1148/radiol.2016152595 [doi]
AB  - Purpose To evaluate the frequency, patterns, and prognostic importance of 
      metastatic hepatic involvement in serous ovarian cancer. Materials and Methods 
      This institutional review board-approved retrospective study, with waived 
      informed consent, included 244 patients with pathologically proven serous ovarian 
      cancer (mean age +/- standard deviation, 59 years +/- 10.7; range 19-93 years). 
      Electronic medical records and all available imaging studies over a median 
      follow-up of 44 months (interquartile range [IQR], 27-70) were reviewed to 
      identify the frequency of liver parenchymal invasion (LPI) from perihepatic 
      peritoneal metastasis and hematogenous liver metastases. The associations and 
      prognostic importance of LPI and hematogenous metastases were studied by using 
      univariate and multivariate Cox proportional analysis. Results Eighty-four of 244 
      patients (34%) developed perihepatic metastases, of whom 55 (23%) developed LPI 
      after median of 43 months (IQR, 25-63). Hematogenous hepatic metastases developed 
      in 38 of 244 patients (16%) after median of 42 months (IQR, 26-64). At 
      multivariate analysis, age (P = .008; hazard ratio [HR]: 1.03; 95% confidence 
      interval [CI]: 1.009, 1.07) and suboptimal cytoreduction (P = .03; HR, 2.13; 95% 
      CI: 1.12, 4.07) were associated with LPI. Increasing age (P = .01; HR, 1.04; 95% 
      CI: 1.008, 1.08), high-grade tumor (P = .01; HR, 6.75; 95% CI: 1.44, 120.5), and 
      advanced stage (P = .03; HR, 3.16; 95% CI: 1.94, 4.56) were associated with 
      hematogenous metastases. Overall survival with and without LPI was similar 
      (median, 80 months; IQR, 50-not reached vs 123 months; IQR, 49-279; P = .6). 
      Hematogenous metastases were associated with significantly shorter survival at 
      univariate (median 63 months, IQR 43-139 vs 145 months, IQR 50-not reached; P = 
      .006) and multivariate analyses (P = .03; HR, 1.88; 95% CI: 1.14, 3.28). 
      Conclusion Differentiating hematogenous metastases and LPI is important for 
      radiologists; hematogenous metastases are associated with shorter survival, while 
      LPI does not adversely affect survival and prognostically behaves like peritoneal 
      disease. ((c)) RSNA, 2016.
FAU - O'Neill, Ailbhe C
AU  - O'Neill AC
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Somarouthu, Bhanusupriya
AU  - Somarouthu B
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Tirumani, Sree Harsha
AU  - Tirumani SH
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Braschi-Amirfarzan, Marta
AU  - Braschi-Amirfarzan M
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Van den Abbeele, Annick D
AU  - Van den Abbeele AD
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Ramaiya, Nikhil H
AU  - Ramaiya NH
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
FAU - Shinagare, Atul B
AU  - Shinagare AB
AD  - From the Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, 
      Boston, MA 02115.
LA  - eng
PT  - Journal Article
DEP - 20160801
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 0 (Contrast Media)
RN  - 4419T9MX03 (Iohexol)
SB  - IM
MH  - Aged
MH  - Contrast Media
MH  - Female
MH  - Humans
MH  - Iohexol
MH  - Liver Neoplasms/*diagnostic imaging/*secondary
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*pathology
MH  - Prognosis
MH  - Radiographic Image Interpretation, Computer-Assisted
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed/*methods
EDAT- 2016/08/02 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
PHST- 2016/08/02 06:00 [entrez]
AID - 10.1148/radiol.2016152595 [doi]
PST - ppublish
SO  - Radiology. 2017 Jan;282(1):160-170. doi: 10.1148/radiol.2016152595. Epub 2016 Aug 
      1.